⚠️ Teaching Case Note: This case has been de-identified and reconstructed for educational purposes. Clinical details reflect real surgical decision-making and outcomes. Patient identity is fully protected.
Central Lung Cancer, Bronchus Invaded, Lymph Nodes Positive — Resected by Robot, Lung Preserved, Home in Four Days
He was 62 years old, a 40-year smoker, with three months of dry cough and a week of blood-streaked sputum. The CT showed a 3.5 cm mass at the right hilum, blocking the upper lobe bronchus and causing lobar collapse. Bronchoscopy confirmed squamous cell carcinoma. The mediastinal nodes at station 4R were enlarged and fused. He was Stage IIIA.
The conventional answer for central lung cancer invading the bronchus is pneumonectomy — removal of the entire right lung. Dr. Hao Wang's team at Shanghai Chest Hospital chose a different path: two cycles of neoadjuvant immunochemotherapy to shrink the tumor, followed by robotic-assisted sleeve lobectomy — removing the upper lobe while reconstructing the bronchus and preserving the middle and lower lobes.
The operation took 165 minutes. Blood loss was 100 mL. There was no conversion to open surgery. The patient was discharged on day four. At 18 months, he was disease-free and jogging.
The Tumor: Central, Obstructing, Node-Positive
Enhanced CT with three-dimensional reconstruction mapped the anatomy precisely. The right upper lobe mass measured 3.5 × 3.0 cm, centered at the hilum. It had invaded the right upper lobe bronchial orifice and the proximal intermediate bronchus, producing complete upper lobe atelectasis. The tumor abutted the right pulmonary artery trunk — fat plane preserved, no encasement, but the margin was narrow.
Mediastinal staging was the critical finding. Station 4R lymph nodes were enlarged and fused, with a short axis of 1.5 cm — morphologically consistent with metastatic involvement. Station 7 (subcarinal) nodes were suspicious. Tumor markers: CEA 15.6 ng/mL, CYFRA21-1 4.8 ng/mL. Bronchoscopic biopsy confirmed moderately differentiated squamous cell carcinoma.
Pulmonary function was adequate: FEV1 2.1 L (78% predicted), DLCO normal. The patient could tolerate lobectomy. He could not tolerate pneumonectomy without significant long-term functional compromise. Clinical staging: cT2N2M0, Stage IIIA.
The MDT Decision: Neoadjuvant Therapy First, Then Sleeve Resection
The multidisciplinary team addressed two questions sequentially: how to manage the N2 disease, and how to resect the primary tumor while preserving lung function.
On N2 management: upfront surgery for bulky, fused station 4R nodes carries a high risk of incomplete resection and poor long-term outcomes. The team elected neoadjuvant immunochemotherapy — two cycles of a PD-1 inhibitor combined with albumin-bound paclitaxel and carboplatin — to downstage the nodal disease, remodel the tumor microenvironment, and improve the probability of R0 resection at surgery.
On surgical strategy: pneumonectomy was rejected as the primary approach. The right middle and lower lobes were uninvolved and functional. Sleeve lobectomy — resecting the upper lobe with a cuff of the main bronchus and intermediate bronchus, then reconstructing the airway by end-to-end anastomosis — would achieve the same oncological margins while preserving two lobes of functioning lung. The trade-off is technical complexity: bronchial anastomosis in a deep, narrow mediastinal space requires precision that exceeds the capability of conventional thoracoscopy.
Dr. Wang's team selected the Da Vinci Xi robotic system for this reason. The 10× magnified three-dimensional view, combined with the seven degrees of freedom of the EndoWrist instruments, enables suture placement and knot tying in confined anatomical spaces that are not accessible with straight VATS instruments. For bronchial sleeve reconstruction specifically, the robotic platform converts a technically prohibitive minimally invasive procedure into a reproducible one.
The Operation: Robotic Sleeve Lobectomy With Systematic Nodal Dissection
Setup. Double-lumen endotracheal intubation for single-lung ventilation. Left lateral decubitus position. Four robotic ports (8–12 mm) on the right chest wall, plus one 3 cm assistant port at the fourth intercostal space, anterior axillary line.
Exploration. The right upper lobe was collapsed and consolidated. No pleural metastatic nodules. The tumor was confirmed at the hilum, abutting but not encasing the pulmonary artery.
Vascular dissection — no-touch technique. The fourth robotic arm retracted the lung without direct tumor contact. The right upper lobe pulmonary artery branches and veins were individually dissected, clipped with Hem-o-lok, and divided — avoiding compression of the tumor and the risk of hematogenous dissemination that comes with direct manipulation of a vascularized mass.
Bronchial sleeve resection. The right main bronchus, intermediate bronchus, and right lower lobe bronchus were mobilized circumferentially. The upper lobe bronchus was divided 1.5 cm from the tumor margin proximally and distally, excising the invaded bronchial orifice and the involved segment of the main bronchial wall en bloc with the upper lobe specimen. Frozen section of both bronchial margins confirmed negative margins before anastomosis was begun.
Bronchial anastomosis. End-to-end anastomosis between the right lower lobe bronchus and the right main bronchus / intermediate bronchus was performed using interrupted 3-0 Prolene sutures under robotic magnification. The anastomosis was constructed without tension — the critical determinant of healing and the primary risk factor for bronchopleural fistula. Total anastomosis time: 35 minutes.
Systematic mediastinal lymph node dissection. Stations 2R, 4R, 7, 10R, and 11R were dissected completely — skeletonization technique, removing all nodal and fibrofatty tissue from the defined anatomical boundaries. The vagus nerve and recurrent laryngeal nerve were identified and preserved throughout the 4R dissection, where fused nodes had partially encased the nerve sheath.
Leak test. The lung was re-inflated under saline. No air leak at the anastomosis. Bronchial vascularity confirmed intact on visual inspection.
Operative data: Total time 165 minutes. Anastomosis time 35 minutes. Estimated blood loss 100 mL. No transfusion. No conversion to open thoracotomy.
Pathology and Recovery
Final pathology: Moderately differentiated squamous cell carcinoma. Both bronchial resection margins negative — R0. Lymph node metastases confirmed at station 4R (3 of 5 nodes) and station 7 (1 of 3 nodes). Pathological staging: ypT2bN2M0, Stage IIIA — consistent with partial nodal response to neoadjuvant therapy.
Recovery followed an ERAS protocol. Paravertebral nerve block was performed intraoperatively; postoperative analgesia was maintained with intravenous PCA, without long-term opioid requirement. The urinary catheter was removed at six hours. Deep breathing exercises and directed cough training began on the day of surgery. Chest drain output was below 200 mL on postoperative day one; chest radiograph confirmed full lung re-expansion; the drain was removed. The patient was discharged on postoperative day four.
No bronchopleural fistula. No cardiac arrhythmia. No recurrent laryngeal nerve injury — voice was normal at discharge.
Follow-Up: Airway Healed, Lung Function Preserved, Disease-Free at 18 Months
At one month: bronchoscopy showed complete anastomotic healing with no stenosis, no granulation tissue, no dehiscence. FEV1 had recovered to 90% of the preoperative value — confirming that the preserved middle and lower lobes had compensated effectively for the resected upper lobe.
Adjuvant therapy: two additional cycles of chemotherapy plus immunotherapy were completed as planned, targeting residual micrometastatic disease in the node-positive mediastinum.
At 18 months: no evidence of disease on CT surveillance. The patient was performing moderate-intensity exercise including jogging — a functional outcome that pneumonectomy would have made impossible.
Expert Commentary — Dr. Hao Wang
"Sleeve lobectomy has always been the oncologically correct operation for central lung cancer invading the bronchus — it achieves the same R0 resection as pneumonectomy while preserving functional lung parenchyma. The reason it was historically performed through thoracotomy is not oncological. It is technical. Bronchial anastomosis in a deep mediastinal space, with interrupted sutures, under direct vision, requires instrument maneuverability that straight thoracoscopic tools cannot provide.
The robotic platform changes that equation. The EndoWrist gives you seven degrees of freedom inside the chest. The 10× magnification makes the anastomotic plane visible in a way that open surgery, paradoxically, does not always achieve. The result is that a procedure which previously required a 20 cm thoracotomy can now be completed through four ports, with equivalent oncological outcomes and substantially faster recovery.
The neoadjuvant immunotherapy decision in this case was not incidental. Bulky N2 disease at station 4R — fused nodes abutting the superior vena cava and trachea — is not safely resectable without prior treatment in most patients. Two cycles of immunochemotherapy converted an unresectable nodal burden into a resectable one. The surgery then completed what the systemic therapy began. That is the MDT model working as it should: each modality doing what it does best, in the right sequence.
This patient is jogging at 18 months. His FEV1 is 90% of preoperative. His anastomosis is patent. That is what lung-preserving surgery is for."
About Dr. Hao Wang
Dr. Hao Wang is a senior thoracic surgeon at Shanghai Chest Hospital, specializing in robotic-assisted and video-assisted thoracoscopic surgery (VATS) for early and advanced lung cancer. He has extensive experience in robotic-assisted lobectomy, sleeve resection, and complex mediastinal tumor resection. Dr. Wang is a key opinion leader in minimally invasive thoracic oncology in China, recognized for his expertise in bronchial reconstruction and systematic mediastinal lymph node dissection in high-complexity cases.
How CMCS Supported This Patient
China Medical Concierge – Shanghai (CMCS) coordinated the full care pathway: specialist matching and priority access to Dr. Wang's team at Shanghai Chest Hospital, multidisciplinary team coordination across thoracic surgery, medical oncology, and pulmonology, Mandarin-English interpretation for all consultations — including the staged informed consent process covering neoadjuvant immunochemotherapy, interval surgical planning, and the specific risks of bronchial sleeve reconstruction — family communication support throughout both the neoadjuvant treatment period and the surgical admission, and long-term follow-up coordination including bronchoscopic surveillance scheduling, pulmonary function testing, and adjuvant therapy planning.
For international patients and expatriates in Shanghai facing central or locally advanced lung cancer — where the sequence of systemic therapy, surgical timing, and airway reconstruction technique determines both oncological outcome and long-term quality of life — CMCS provides end-to-end support from initial staging to 18-month surveillance and beyond.
0 則留言